Literature DB >> 15657071

Rituximab inefficiency during type I cryoglobulinaemia.

H Nehme-Schuster, A-S Korganow, J-L Pasquali, T Martin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15657071     DOI： 10.1093/rheumatology/keh503

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  8 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 2.  Non-infectious cryoglobulinemia vasculitis (CryoVas): update on clinical and therapeutic approach.

Authors:  Rodolfo Perez-Alamino; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2014-05       Impact factor: 4.592

3.  Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia.

Authors:  Aisha Shaikh; Thomas M Habermann; Mary E Fidler; Shaji Kumar; Nelson Leung
Journal:  Clin Exp Nephrol       Date:  2008-02-22       Impact factor: 2.801

4.  Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab.

Authors:  David Chu; Michelle Stevens; Douglas Edward Gladstone
Journal:  Rheumatol Int       Date:  2007-04-19       Impact factor: 2.631

5.  Leukocytoclastic vasculitis in a patient with type 1 cryoglobulinemia.

Authors:  Paul Y Liu; Pamela E Prete; Gary Kukes
Journal:  Case Rep Rheumatol       Date:  2011-10-10

Review 6.  Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature.

Authors:  Freke Wink; Pieternella M Houtman; Tim L Th A Jansen
Journal:  Clin Rheumatol       Date:  2010-10-31       Impact factor: 3.650

Review 7.  IgM monoclonal gammopathies of clinical significance: diagnosis and management.

Authors:  Jahanzaib Khwaja; Shirley D'Sa; Monique C Minnema; Marie José Kersten; Ashutosh Wechalekar; Josephine M Vos
Journal:  Haematologica       Date:  2022-09-01       Impact factor: 11.047

8.  A case of essential mixed cryoglobulinemia and associated acquired von-Willebrand disease treated with rituximab.

Authors:  Semir Pasa; Abdullah Altintas; Timucin Cil; Ramazan Danis; Orhan Ayyildiz; Ekrem Muftuoglu
Journal:  J Thromb Thrombolysis       Date:  2008-01-13       Impact factor: 5.221
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.